You have to be registered and logged in for purchasing articles.

Abstract

Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry Method Using Different Monoclonal Antibodies in Colorectal Cancer Patients by Fan Chi-Chen, Wang Tao-Yeuan, Kung Chien-Min

Background: Targeted therapy is typically used to treat colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) was recognized as a potential therapeutic target. Does the EGFR protein express consistently using different monoclonal antibodies in clinics?
Methods: One hundred and sixty-four patients (mean age 61.80 ± 12.78 years) who suffered from CRC were selected at Mackay Memorial Hospital in Taiwan. Formalin-fixed and paraffin-embedded tissue sections from all patients were tested simultaneously using two commercial antibodies, Dako-EGFR (mouse monoclonal anti-EGFR clone 2-18C9, pharmDxTM) and NCL-EGFR (NCL-EGFR-384, NovocastraTM) monoclonal antibodies, to study the commutability or equality of the qualities of EGFR expression by standard immunohistochemistry (IHC) procedures.
Results: The EGFR expressions that were obtained by IHC staining using different monoclonal antibodies with Dako-EGFR (46.95%) and NCL-EGFR (32.32%) were fairly concordant.
Conclusions: Although IHC is a convenient and feasible method for detecting the expression of EGFR, it yields controversial staining results concerning EGFR expression using various commercial antibodies in a CRC tumor section.

DOI: 10.7754/Clin.Lab.2015.150330